公开(公告)号：US10772864B2

公开(公告)日：2020-09-15

申请号：US16284461

申请日：2019-02-25

申请人： Biosuccess Biotech Co., Ltd.

发明人： Hung-Fong Chen ,  Zheng Tao Han

IPC分类号： A61K31/23 ,  A61K31/21 ,  A61K31/216 ,  A61K31/235 ,  A61K31/225 ,  A61K45/06 ,  A61K31/573 ,  A61K31/603 ,  A61K31/22 ,  A61K31/381 ,  A61K31/55 ,  A61P25/14 ,  A61P25/28

摘要： Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequalae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

公开(公告)号：US20200000755A1

公开(公告)日：2020-01-02

申请号：US16458843

申请日：2019-07-01

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Alonso G. P. Guedes ,  Bruce D. Hammock ,  Christophe Morisseau

IPC分类号： A61K31/196 ,  A61K31/167 ,  A61K31/17 ,  A61K31/192 ,  A61K31/197 ,  A61K31/405 ,  A61K45/06 ,  A61K31/4152 ,  A61K31/451 ,  A61K31/513 ,  A61K31/5415 ,  A61K31/603 ,  A61K31/415

摘要： The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.

公开(公告)号：US10449169B2

公开(公告)日：2019-10-22

申请号：US16101882

申请日：2018-08-13

申请人： SOM INNOVATION BIOTECH, S.L.

发明人： Marc Centellas Casado ,  Raúl Insa Boronat ,  Núria Reig Bolano ,  Nuria Gavaldà Batalla

IPC分类号： A61K31/165 ,  C07D263/58 ,  C07D263/20 ,  A61K31/198 ,  A61K45/06 ,  A61K31/12 ,  A61K31/353 ,  A61K31/423 ,  A61K31/603 ,  A61K31/192

摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

公开(公告)号：US10420756B2

公开(公告)日：2019-09-24

申请号：US15074524

申请日：2016-03-18

申请人： Jacqueline M. Iversen ,  James M. Iversen

发明人： Jacqueline M. Iversen ,  James M. Iversen

IPC分类号： A61K31/192 ,  A61K31/445 ,  A61K9/00 ,  A61K45/06 ,  A61K31/196 ,  A61K31/407 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/60 ,  A61K31/603

摘要： The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.

公开(公告)号：US10045956B2

公开(公告)日：2018-08-14

申请号：US15448054

申请日：2017-03-02

申请人： SOM INNOVATION BIOTECH, S.L.

发明人： Marc Centellas Casado ,  Raúl Insa Boronat ,  Núria Reig Bolano ,  Nuria Gavaldà Batalla

IPC分类号： A61K31/42 ,  A61K31/165 ,  A61K31/16 ,  A61K31/198 ,  A61K45/06 ,  A61K31/12 ,  A61K31/353 ,  A61K31/423 ,  A61K31/603 ,  A61K31/192

摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

公开(公告)号：US20170319533A1

公开(公告)日：2017-11-09

申请号：US15658730

申请日：2017-07-25

申请人： Biosuccess Biotech Co., Ltd.

发明人： Hung-Fong CHEN ,  Zheng Tao HAN

IPC分类号： A61K31/225 ,  A61K45/06 ,  A61K31/22 ,  A61K31/216 ,  A61K31/55 ,  A61K31/381 ,  A61K31/573 ,  A61K31/603

CPC分类号： A61K31/225 ,  A61K31/216 ,  A61K31/22 ,  A61K31/381 ,  A61K31/55 ,  A61K31/573 ,  A61K31/603 ,  A61K45/06 ,  A61K2300/00

摘要： Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

公开(公告)号：US20160120883A1

公开(公告)日：2016-05-05

申请号：US14930512

申请日：2015-11-02

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： Michael R. YEAMAN ,  Arnold S. BAYER

IPC分类号： A61K31/60 ,  A61K31/603 ,  A61K38/14 ,  A61K31/5377

CPC分类号： A61K31/60 ,  A61K31/5377 ,  A61K31/603 ,  A61K38/14 ,  Y02A50/402 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/481 ,  Y02A50/483

摘要： The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). The invention also provides a method for preventing or treating an infectious disease caused by of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) or vancomycin-resistant Staphylococcus aureus (VRSA), comprising systemically co-administering in a synergistic combination to a subject in need thereof prophylactically or therapeutically effective amounts, individually or collectively, of a salicylic acid (SAL) or a SAL analogue and at least one additional antimicrobial agent, for example, vancomycin and/or linezolid.

摘要翻译： 本发明提供了一种预防或治疗由细胞外微生物引起的疾病的方法，所述方法包括向有需要的受试者全身施用预防或治疗有效量的水杨酸（SAL）或SAL类似物。 细胞外微生物可以是细菌属葡萄球菌，例如金黄色葡萄球菌。 细胞外微生物可以是对至少一种抗生素具有抗性的菌株。 该菌株可以选自耐甲氧西林金黄色葡萄球菌（MRSA），万古霉素 - 中间体金黄色葡萄球菌（VISA）和耐万古霉素金黄色葡萄球菌（VRSA）。 本发明还提供一种预防或治疗由耐甲氧西林金黄色葡萄球菌（MRSA），万古霉素中间体金黄色葡萄球菌（VISA）或万古霉素耐药金黄色葡萄球菌（VRSA）引起的感染性疾病的方法，其包括全身共同施用于 对需要其的预防或治疗有效量的水杨酸（SAL）或SAL类似物和至少一种另外的抗微生物剂例如万古霉素和/或利奈唑胺的预防或治疗有效量的协同组合。

公开(公告)号：US20150182434A1

公开(公告)日：2015-07-02

申请号：US14408676

申请日：2014-03-11

申请人： Avon Products, Inc.

发明人： Hong Hu ,  Kai Xi ,  Sung Bin Shin

IPC分类号： A61K8/368 ,  A61Q19/00 ,  G01N33/573 ,  A61Q19/02 ,  A61K31/603 ,  A61Q19/08 ,  A61Q17/00

CPC分类号： A61K8/368 ,  A61K31/07 ,  A61K31/192 ,  A61K31/203 ,  A61K31/603 ,  A61K2800/28 ,  A61K2800/592 ,  A61K2800/78 ,  A61Q17/00 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/08 ,  G01N33/573 ,  G01N2333/96433 ,  G01N2500/04 ,  G01N2500/20

摘要： Cosmetic compositions comprising napthoic acid derivatives and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The napthoic acid derivatives are believed to have modulatory activity against one or more biochemical pathways implicated in the appearance of human skin.

摘要翻译： 公开了包含萘酚酸衍生物的化妆品组合物和使用这些组合物赋予皮肤抗衰老益处的方法。 据信萘甲酸衍生物对于涉及人皮肤外观的一种或多种生物化学途径具有调节活性。

公开(公告)号：US08541398B2

公开(公告)日：2013-09-24

申请号：US12704412

申请日：2010-02-11

申请人： John L. Wallace ,  Giuseppe Cirino ,  Vincenzo Santagada ,  Giuseppe Caliendo

发明人： John L. Wallace ,  Giuseppe Cirino ,  Vincenzo Santagada ,  Giuseppe Caliendo

IPC分类号： A61K31/603 ,  A61K31/606 ,  C07D209/04 ,  C07C69/76

CPC分类号： C07C219/14 ,  C07C327/48 ,  C07D209/18 ,  C07D209/32 ,  C07D309/30 ,  C07D339/04 ,  C07D409/12

摘要： The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.

摘要翻译： 本发明涉及具有改善抗炎性质的非甾体抗炎药（NSAID）的衍生物，其可用于治疗炎症，疼痛和发烧。 更具体地，NSAID用硫化氢（H 2 S）释放部分衍生化，以产生具有降低的副作用的新型抗炎化合物。

公开(公告)号：US20120028930A1

公开(公告)日：2012-02-02

申请号：US13035663

申请日：2011-02-25

申请人： Isabel KALOFONOS ,  William Martin Doyle

发明人： Isabel KALOFONOS ,  William Martin Doyle

IPC分类号： A61K31/44 ,  A61P21/00 ,  A61P25/00 ,  A61P9/12 ,  C07D213/75 ,  A61K31/603

CPC分类号： A61K31/44 ,  C07D213/75

摘要： The present invention includes salts and polymorphs of flupirtine including, but not limited to carboxylic acid salts and sulfonic acid salts and their polymorphs. The present invention also includes pharmaceutical compositions comprising the salts and polymorphs of flupirtine. The invention also relates to the therapeutic use of the flupirtine salts and polymorphs to treat nervous system disorders, pain disorders, musculoskeletal disorders, and other diseases and conditions.

摘要翻译： 本发明包括氟吡汀的盐和多晶型物，包括但不限于羧酸盐和磺酸盐及其多晶型物。 本发明还包括包含氟吡汀的盐和多晶型物的药物组合物。 本发明还涉及氟吡汀盐和多晶型物治疗神经系统疾病，疼痛障碍，肌肉骨骼疾病和其它疾病和病症的治疗用途。